Literature DB >> 17955440

Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial.

Katherine L O'Brien1, Eugene V Millar, Elizabeth R Zell, Melinda Bronsdon, Robert Weatherholtz, Raymond Reid, Jocelyn Becenti, Sheri Kvamme, Cynthia G Whitney, Mathuram Santosham.   

Abstract

BACKGROUND: Pneumococcal conjugate vaccines (PCVs) prevent vaccine serotype (VT) invasive disease; nonvaccine serotype (NVT) disease increases modestly. The impact of PCV on nasopharyngeal (NP) colonization is essential to understanding disease effects.
METHODS: We conducted a community-randomized controlled trial with catch-up vaccination through age 2 years investigating the effect of 7-valent PCV (PnCRM7) on NP colonization among American Indian infants and their unvaccinated contacts. Infants receiving blinded vaccine at 2, 4, 6, and 12-15 months of age had NP cultures obtained at age 7, 12, and 18 months. Serotype-specific colonization was detected by immunoblot.
RESULTS: We enrolled 566 vaccinated and 286 unvaccinated children from 511 households and collected 5157 specimens, of which 3525 (68.4%) had pneumococcus. PnCRM7 vaccinees were less likely to be colonized with VT (odds ratio [OR], 0.40 [95% confidence interval {CI}, 0.23-0.67]) but were more likely to be colonized with NVT pneumococci (OR, 1.67 [95% CI, 1.02-2.78]). PnCRM7 vaccinees were less densely colonized with VT strains than control vaccinees (OR, 0.61 [95% CI, 0.38-0.99]). Day care-attending unvaccinated children in PnCRM7 communities were less likely to have VT colonization than those in control communities (OR, 0.27 [95% CI, 0.07-1.07]).
CONCLUSIONS: PnCRM7 reduces the risk of VT acquisition and colonization density but increases the risk of NVT acquisition among vaccinees and their household contacts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17955440     DOI: 10.1086/521833

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  90 in total

1.  Association of serotype-specific antibody concentrations and functional antibody titers with subsequent pneumococcal carriage in toddlers immunized with a 9-valent pneumococcal conjugate vaccine.

Authors:  Birgit Simell; Anu Nurkka; Mika Lahdenkari; Noga Givon-Lavi; Helena Käyhty; Ron Dagan; Jukka Jokinen
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

2.  A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Authors:  Rolando Pajon; Carolyn M Buckwalter; Kay O Johswich; Scott D Gray-Owen; Dan M Granoff
Journal:  Vaccine       Date:  2015-02-04       Impact factor: 3.641

Review 3.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

4.  Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine.

Authors:  Marc Lipsitch; Keith O'Neill; Derrick Cordy; Boris Bugalter; Krzysztof Trzcinski; Claudette M Thompson; Richard Goldstein; Stephen Pelton; Heather Huot; Valerie Bouchet; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  J Infect Dis       Date:  2007-09-17       Impact factor: 5.226

5.  Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway.

Authors:  Didrik F Vestrheim; E Arne Høiby; Ingeborg S Aaberge; Dominique A Caugant
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

6.  Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts.

Authors:  Grace M Lee; Ken Kleinman; Stephen I Pelton; William Hanage; Susan S Huang; Matthew Lakoma; Maya Dutta-Linn; Nicholas J Croucher; Abbie Stevenson; Jonathan A Finkelstein
Journal:  J Pediatric Infect Dis Soc       Date:  2013-10-03       Impact factor: 3.164

7.  Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines.

Authors:  Nicola Principi; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Using pneumococcal carriage data to monitor postvaccination changes in invasive disease.

Authors:  Daniel M Weinberger; Dana T Bruden; Lindsay R Grant; Marc Lipsitch; Katherine L O'Brien; Stephen I Pelton; Elisabeth A M Sanders; Daniel R Feikin
Journal:  Am J Epidemiol       Date:  2013-09-07       Impact factor: 4.897

Review 9.  Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

Authors:  William P Hausdorff; Bernard Hoet; Lode Schuerman
Journal:  BMC Pediatr       Date:  2010-02-02       Impact factor: 2.125

10.  Multiple colonization with S. pneumoniae before and after introduction of the seven-valent conjugated pneumococcal polysaccharide vaccine.

Authors:  Silvio D Brugger; Pascal Frey; Suzanne Aebi; Jason Hinds; Kathrin Mühlemann
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.